Robeco Institutional Asset Management B.V. Arcus Biosciences, Inc. Transaction History

Robeco Institutional Asset Management B.V.

$51.9 Billion
Q4 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 24, 2023	SELL	$16.97 - $22.03 $922,591 - $1.2 Million	-54,366 Reduced 97.94%	1,143 $23,000
Q1 2023 May 03, 2023	BUY	$15.96 - $23.15 $151,875 - $220,295	9,516 Added 20.69%	55,509 $1.01 Million
Q4 2022 Feb 06, 2023	BUY	$19.7 - $35.71 $313,033 - $567,431	15,890 Added 52.79%	45,993 $951,000
Q3 2022 Dec 01, 2022	BUY	$23.23 - $30.07 $219,012 - $283,499	9,428 Added 45.6%	30,103 $788,000
Q3 2022 Oct 26, 2022	BUY	$23.23 - $30.07 $219,012 - $283,499	9,428 Added 45.6%	30,103 $788,000
Q2 2022 Dec 01, 2022	SELL	$17.23 - $37.73 $162,444 - $355,718	-9,428 Reduced 31.32%	20,675 $524,000
Q2 2022 Jul 27, 2022	BUY	$17.23 - $37.73 $356,230 - $780,067	20,675 New	20,675 $524,000

Others Institutions Holding RCUS

# of Institutions

200

Shares Held

51.5M

Call Options Held

236K

Put Options Held

141K

Black Rock Inc. New York, NY

9.76M
Shares

$128 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

5.47M
Shares

$72 Million
0.0% of portfolio
Woodline Partners LP San Francisco, CA

3.48M
Shares

$45.8 Million
0.48% of portfolio
State Street Corp Boston, MA

3.01M
Shares

$39.6 Million
0.0% of portfolio
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct

2.44M
Shares

$32.1 Million
0.1% of portfolio

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $950M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Robeco Institutional Asset Management B.V., based on Form 13F filings with the SEC.

News

Stay updated on Robeco Institutional Asset Management B.V. with notifications on news.

Account